bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Recommendation of “Hold” from Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have earned a consensus rating of “Hold” from the eight brokerages that are covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $44.60.

A number of research analysts recently issued reports on BLUE shares. Baird R W cut shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. Wells Fargo & Company decreased their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. Barclays lowered their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. StockNews.com began coverage on bluebird bio in a research note on Monday. They set a “sell” rating on the stock. Finally, JPMorgan Chase & Co. raised shares of bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th.

Institutional Trading of bluebird bio

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares in the last quarter. State Street Corp boosted its stake in shares of bluebird bio by 1.1% during the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares in the last quarter. Barclays PLC boosted its position in bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after buying an additional 184,605 shares during the period. Finally, Regeneron Pharmaceuticals Inc. acquired a new position in shares of bluebird bio during the fourth quarter worth $175,000. Institutional investors own 87.43% of the company’s stock.

bluebird bio Price Performance

Shares of BLUE stock opened at $3.90 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. bluebird bio has a 52-week low of $3.56 and a 52-week high of $28.60. The firm’s 50 day moving average price is $4.59 and its two-hundred day moving average price is $7.04. The stock has a market cap of $38.18 million, a PE ratio of -0.10 and a beta of 0.41.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.